Impact of Tumour Epstein–Barr Virus Status on ClinicalOutcome in Patients with Classical Hodgkin Lymphoma (cHL):A Review of the Literature and Analysis of a Clinical TrialCohort of Children with cHL

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F22%3A73617245" target="_blank" >RIV/61989592:15110/22:73617245 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454639/pdf/cancers-14-04297.pdf" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454639/pdf/cancers-14-04297.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/cancers14174297" target="_blank" >10.3390/cancers14174297</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Impact of Tumour Epstein–Barr Virus Status on ClinicalOutcome in Patients with Classical Hodgkin Lymphoma (cHL):A Review of the Literature and Analysis of a Clinical TrialCohort of Children with cHL

Popis výsledku v původním jazyce

In this study, we have re-evaluated how EBV status influences clinical outcome. Toaccomplish this, we performed a literature review of all studies that have reported the effect of EBVstatus on patient outcome and also explored the effect of EBV positivity on outcome in a clinical trialof children with cHL from the UK. Our literature review revealed that almost all studies of olderadults/elderly patients have reported an adverse effect of an EBV-positive status on outcome. Inyounger adults with cHL, EBV-positive status was either associated with a moderate beneficial effector no effect, and the results in children and adolescents were conflicting. Our own analysis of a seriesof 166 children with cHL revealed no difference in overall survival between EBV-positive and EBV-negative groups (p= 0.942, log rank test). However, EBV-positive subjects had significantly longerevent-free survival (p= 0.0026). Positive latent membrane protein 1 (LMP1) status was associatedwith a significantly lower risk of treatment failure in a Cox regression model (HR = 0.21,p= 0.005). Inmodels that controlled for age, gender, and stage, EBV status had a similar effect size and statisticalsignificance. This study highlights the age-related impact of EBV status on outcome in cHL patientsand suggests different pathogenic effects of EBV at different stages of life

Název v anglickém jazyce

Impact of Tumour Epstein–Barr Virus Status on ClinicalOutcome in Patients with Classical Hodgkin Lymphoma (cHL):A Review of the Literature and Analysis of a Clinical TrialCohort of Children with cHL

Popis výsledku anglicky

In this study, we have re-evaluated how EBV status influences clinical outcome. Toaccomplish this, we performed a literature review of all studies that have reported the effect of EBVstatus on patient outcome and also explored the effect of EBV positivity on outcome in a clinical trialof children with cHL from the UK. Our literature review revealed that almost all studies of olderadults/elderly patients have reported an adverse effect of an EBV-positive status on outcome. Inyounger adults with cHL, EBV-positive status was either associated with a moderate beneficial effector no effect, and the results in children and adolescents were conflicting. Our own analysis of a seriesof 166 children with cHL revealed no difference in overall survival between EBV-positive and EBV-negative groups (p= 0.942, log rank test). However, EBV-positive subjects had significantly longerevent-free survival (p= 0.0026). Positive latent membrane protein 1 (LMP1) status was associatedwith a significantly lower risk of treatment failure in a Cox regression model (HR = 0.21,p= 0.005). Inmodels that controlled for age, gender, and stage, EBV status had a similar effect size and statisticalsignificance. This study highlights the age-related impact of EBV status on outcome in cHL patientsand suggests different pathogenic effects of EBV at different stages of life

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/EF16_019%2F0000868" target="_blank" >EF16_019/0000868: Molekulární, buněčný a klinický přístup ke zdravému stárnutí</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cancers

ISSN

2072-6694

e-ISSN

—

Svazek periodika

14

Číslo periodika v rámci svazku

17

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

15

Strana od-do

4297

Kód UT WoS článku

000851059200001

EID výsledku v databázi Scopus

2-s2.0-85137767728